Explore P21 dosage trends, reconstitution volumes, and vial size patterns from anonymized WPA peptide calculator data.
P21 (also written P021) is a small tetrapeptide derived from the active region of ciliary neurotrophic factor (CNTF), developed in Khalid Iqbal's laboratory at the New York State Institute for Basic Research in Developmental Disabilities as an orally bioavailable, brain-penetrant neurogenic agent for Alzheimer's disease.
P21 mimics the neurogenic, but not the pro-inflammatory or cachexia-inducing, activity of CNTF. Iqbal's group reports that P21 enhances hippocampal neurogenesis, increases BDNF expression, and inhibits leukaemia inhibitory factor (LIF) signalling, producing a dissociated neurotrophic profile not seen with CNTF itself.
Pre-clinical work in 3xTg-AD, Alzheimer's, Down syndrome, and traumatic-brain-injury mouse models has reported rescued cognitive performance, reduced tau hyperphosphorylation, and increased adult hippocampal neurogenesis. No registered human clinical trial has been conducted.
P21 has a reported half-life of ~few hours (estimated), and the dose intervals researchers model most often fall around once daily. This CNTF-derived neurogenic peptidomimetic has short plasma exposure, so daily dosing acts per-dose; published human PK is not available. It is catalogued under Memory Peptides on WPA.
10 P21 reconstitution calculations have been logged by the WPA community. The most common dose entered is 250mcg (8 calculations). The most common bacteriostatic water volume is 2mL. The most popular vial size is 10mg (6 sessions). The most common dosing frequency is once weekly (6 logged protocols).
These figures come from anonymized WPA peptide calculator sessions.
All figures shown are aggregated from anonymized calculator inputs and are provided strictly for independent laboratory research and educational purposes. They are community usage statistics — not dosing recommendations, and not medical advice.